focu list chang
npe cut overshadow sovereign spread lower isp estim target price
lse euronext top pick statement revis estim target price
sharper focu storm lower estim
upgrad neutral under-perform estim re-acceler nna merger potenti rais est nd tp
holt reveal food stock cheaper sale growth improv
rise nim nam initi coverag
ride wafer price uplift initi coverag outperform rate target price fo
review batteri busi grow faster expect ev orderbook jump tn rais estim
profit alert impli np slightli ahead cs expect diverg trend continu
thought recent market movement maintain current cautiou view
week key event eye eisai shionogi ono chugai sumitomo dainippon pharma
analyst disclosur credit suiss seek busi compani cover research
report result investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest
npe cut overshadow sovereign spread lower isp estim target price
see two main trend sharp npe reduct driven three main deal mp banco bpm
bper expect aggreg gross npe ratio declin ii sovereign spread widen
driven polit uncertainti spread uplift seem new normal
lse euronext top pick statement revis estim target price
ahead statement reiter outperform rate lse euronext view two
attract growth valu play respect sector remain cautiou neutral rate trader
under-perform rate bme consensu earn downsid risk
sharper focu storm lower estim
yesterday strateg review robust larg sensibl result recent dispos remind
current challeng commenc share buy-back programm market cap appear
prematur leav target price unchang reiter under-perform rate
upgrad neutral under-perform estim re-acceler nna merger potenti rais est nd tp
upgrad neutral rel valuat longer justifi under-perform rate also estim
organ growth net new asset acceler given scottrade-rel attrit peak last quarter
improv
cs view juli host group meet manag compani cincinnati headquart
session rodney mcmullen ceo mike schlotman cfo yael cosset group vice presid chief digit
offic stuart aitken group vice presid head cover broad rang topic summar
report
holt reveal food stock cheaper sale growth improv
dramat pullback food stock price-to-earnings multipl sinc last year appear signal valu opportun
investor cs holt cash flow valuat framework indic market still expect overli optimist
fundament outlook given challeng busi environ
would like receiv product pleas call product market london
follow yesterday news uk regul would review practic payment acquir facilit
provid updat thought impact
rise nim nam initi coverag
initi vietnam bank overweight stanc outperform rate vpb mbb
neutral rate expect vpb mbb bigger beneficiari thrust toward consum lend
also stronger fee incom growth drive higher earn growth rel next two year
ride wafer price uplift initi coverag outperform rate target price fo
growth good margin initi coverag globalwaf outperform rate target price
base ev/ebitda multipl price-to-earnings support cs holt upsid
review batteri busi grow faster expect ev orderbook jump tn rais estim
lg chem report op bn qoq line consensu solid result mainli attribut
success pass-through downstream product support chemic divis top line qoq faster-
than-expect qoq vs cse revenu growth energi solut
profit alert impli np slightli ahead cs expect diverg trend continu
sinopec issu profit alert juli expect net profit rise yoy prc account
suggest net profit impli net profit yoy qoq ahead
cs estim note preview
thought recent market movement maintain current cautiou view
continu see ccm camera modul develop key driver focu improv ccm product
mix client mix gm maintain tp estim remain cautiou outlook wait colour
full result tp hk base histor averag price-to-earnings ep
would like receiv product pleas call product market london
mitsubishi motor post apr-jun result juli op yoy
forecast market consensu leav posit impress
week key event eye eisai shionogi ono chugai sumitomo dainippon pharma
thursday juli see pharma sector result announc kick earnest week
juli also see number import event oversea needless say event interest involv
eisai alzheim drug jointli develop
june medicar data patholog non-hospit patient episod initi growth proxi gp/specialist patholog
referr roll basi flat may patholog outlay growth remain five-
would like receiv product pleas call product market london
headlin price previou day close unless otherwis note
compani mention price jul
